Free Trial
NYSE:RFL

Rafael (RFL) Stock Price, News & Analysis

Rafael logo
$2.03 +0.08 (+4.10%)
(As of 11/21/2024 ET)

About Rafael Stock (NYSE:RFL)

Key Stats

Today's Range
$1.94
$2.03
50-Day Range
$1.54
$2.37
52-Week Range
$1.29
$2.50
Volume
44,139 shs
Average Volume
28,433 shs
Market Capitalization
$50.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

Rafael Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
9th Percentile Overall Score

RFL MarketRank™: 

Rafael scored higher than 9% of companies evaluated by MarketBeat, and ranked 914th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Rafael.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Rafael is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Rafael is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Rafael has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Rafael's valuation and earnings.
  • Percentage of Shares Shorted

    0.29% of the outstanding shares of Rafael have been sold short.
  • Short Interest Ratio / Days to Cover

    Rafael has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Rafael has recently decreased by 3.32%, indicating that investor sentiment is improving.
  • Dividend Yield

    Rafael does not currently pay a dividend.

  • Dividend Growth

    Rafael does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.29% of the outstanding shares of Rafael have been sold short.
  • Short Interest Ratio / Days to Cover

    Rafael has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Rafael has recently decreased by 3.32%, indicating that investor sentiment is improving.
  • News Sentiment

    Rafael has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 25 news articles for Rafael this week, compared to 26 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Rafael insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.70% of the stock of Rafael is held by insiders.

  • Percentage Held by Institutions

    Only 11.30% of the stock of Rafael is held by institutions.

  • Read more about Rafael's insider trading history.
Receive RFL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rafael and its competitors with MarketBeat's FREE daily newsletter.

RFL Stock News Headlines

JD Vance Predicts: Wall Street vs. Trump & Your Money
Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
See More Headlines

RFL Stock Analysis - Frequently Asked Questions

Rafael's stock was trading at $1.83 at the beginning of 2024. Since then, RFL stock has increased by 10.9% and is now trading at $2.03.
View the best growth stocks for 2024 here
.

Rafael Holdings, Inc. (NYSE:RFL) issued its quarterly earnings results on Tuesday, March, 12th. The company reported ($0.08) EPS for the quarter. The firm earned $1.02 million during the quarter. Rafael had a negative trailing twelve-month return on equity of 43.68% and a negative net margin of 5,401.88%.

Top institutional investors of Rafael include Geode Capital Management LLC (0.60%).
View institutional ownership trends
.

Shares of RFL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rafael investors own include NVIDIA (NVDA), Broadcom (AVGO), CrowdStrike (CRWD), ServiceNow (NOW), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
3/12/2019
Today
11/21/2024
Next Earnings (Estimated)
12/12/2024
Fiscal Year End
7/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

Net Income
$-34,410,000.00
Net Margins
-5,401.88%
Pretax Margin
-10,559.03%

Debt

Sales & Book Value

Annual Sales
$640,000.00
Book Value
$3.51 per share

Miscellaneous

Free Float
22,281,000
Market Cap
$50.08 million
Optionable
Optionable
Beta
1.08
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

This page (NYSE:RFL) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners